Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.
Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, Xu M, Boswell HS.
Sayar H, et al. Among authors: cripe ld.
Oncotarget. 2017 Dec 25;9(5):5703-5715. doi: 10.18632/oncotarget.23655. eCollection 2018 Jan 19.
Oncotarget. 2017.
PMID: 29464028
Free PMC article.